Two proteins present in the blood and brains of patients with Huntington’s disease may be used as biomarkers to detect the earliest changes caused by the disease, according to recent research. The study, “Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease,” was published…
Active Biotech. has regained global development and commercialization rights of laquinimod, an investigational immunotherapy for neurodegenerative diseases, including Huntington’s disease (HD) and multiple sclerosis (MS). The move came after Teva Pharmaceutical, the company that previously held laquinimod’s rights, decided not to continue its clinical development. After several years…
An investigational compound called VU0409551 could reverse memory deficiencies and improve learning, according to the results of a mouse study in Huntington’s disease. The study, “The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington’s disease,” was published in the Journal…
CHDI Foundation has teamed up with PTC Therapeutics to try to advance PTC’s work on small-molecule compounds that can reduce the production of huntingtin, the protein responsible for Huntington’s disease. The compounds have shown promise. They decreased the protein in a mouse model carrying the human huntingtin gene. And they…
Get regular updates to your inbox.